Sulsa Therapeutics is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies that target Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases, particularly inflammatory bowel disease. The company's lead program, SL-325, is designed to block the DR3/TL1A pathway more completely and durably than existing TL1A-blocking antibodies, with preclinical evidence suggesting advantages in durability, a lower immunogenicity profile, improved safety, and potential for extended dosing intervals. The company generates revenue through clinical development and commercialization of its proprietary antibody candidates, which are manufactured through contract manufacturing partnerships, with the goal of establishing SL-325 as a disease-modifying monotherapy or combination treatment in the inflammatory bowel disease market.